Related by context. All words. (Click for frequent words.) 79 adjuvant chemotherapy 75 neoadjuvant chemotherapy 73 chemoradiotherapy 73 adjuvant radiation 73 hormonal therapy 72 chemoradiation 72 neoadjuvant therapy 71 adjuvant radiotherapy 71 lymph node dissection 70 trastuzumab 70 postoperative chemotherapy 70 androgen deprivation 69 neoadjuvant 69 gemcitabine 69 adjuvant therapies 69 tamoxifen therapy 68 EBRT 68 preoperative chemotherapy 68 sentinel lymph node biopsy 68 cytotoxic chemotherapy 68 GnRH agonists 68 lymphadenectomy 68 neoadjuvant treatment 67 metastatic RCC 67 brain metastases 67 resectable 67 debulking surgery 67 distant metastases 67 cytoreduction 67 locoregional recurrence 67 chemotherapy regimens 66 locoregional 66 antiplatelet therapy 66 docetaxel 66 androgen suppression 66 cystectomy 66 bevacizumab 66 metastatic disease 66 taxane therapy 66 standard chemotherapy regimens 66 gefitinib 66 cetuximab 66 postoperative radiotherapy 66 Adjuvant chemotherapy 66 mRCC 66 metastatic renal cell carcinoma 66 temsirolimus 66 external beam radiotherapy 66 carboplatin paclitaxel 66 cytoreductive surgery 65 NSCLC 65 androgen ablation 65 glycoprotein IIb IIIa inhibitors 65 sorafenib Nexavar 65 FOLFOX 65 chemotherapeutic regimens 65 adjuvant tamoxifen 65 HER2 positive metastatic breast 65 mycophenolate mofetil 65 ALND 65 pelvic lymphadenectomy 65 vandetanib 65 SLNB 65 chemoradiation therapy 65 curative resection 65 subgroup analyzes 65 bevacizumab Avastin 65 biochemical recurrence 65 localized prostate cancer 65 nab paclitaxel 64 unresectable 64 cisplatin 64 recurrent GBM 64 relapsed ovarian cancer 64 KRAS status 64 recurrent glioblastoma multiforme 64 chemoembolization 64 TACE 64 5FU 64 HER2 negative 64 bortezomib 64 pegylated liposomal doxorubicin 64 hepatic metastases 64 gemcitabine chemotherapy 64 prostate cancer CRPC 64 liver metastases 64 ICD implantation 64 lipid lowering therapy 64 chemotherapy regimen 64 axillary dissection 64 sunitinib 64 gemcitabine Gemzar 64 lymph node metastases 64 adecatumumab 64 carboplatin 64 clinically localized prostate 64 antiviral therapy 64 MGd 64 endocrine therapy 64 micrometastases 64 metastatic colorectal cancer 64 metastatic breast cancer 64 radical nephrectomy 64 radical prostatectomy 64 prospectively defined 64 Doxil ® 63 DMARD 63 pneumonectomy 63 breast conserving 63 recurrent prostate cancer 63 endometrial carcinoma 63 pancreatic adenocarcinoma 63 tamoxifen 63 liver resection 63 sentinel node biopsy 63 colorectal liver metastases 63 platinum refractory 63 surgical debulking 63 docetaxel chemotherapy 63 operable breast cancer 63 trabectedin 63 cisplatin chemotherapy 63 prognostic variables 63 antibiotic prophylaxis 63 cyclophosphamide 63 FDG PET 63 pemetrexed 63 allogeneic stem cell 63 prognostic factors 63 methotrexate therapy 63 intravesical therapy 63 ixabepilone 63 stage IIIB 63 heavily pretreated 63 tumor resection 63 lymph node involvement 63 FOLFOX4 63 pertuzumab 63 5-FU/LV 63 mCRC patients 63 HER2 positive 63 PSADT 63 axillary lymph node dissection 63 epirubicin 63 ABVD 63 imatinib therapy 63 axillary node dissection 63 tumor recurrence 63 radiotherapy RT 63 liposomal doxorubicin 63 cytoreductive nephrectomy 63 zoledronic acid 63 fulvestrant 63 prostate cancer CaP 63 hormonal therapies 62 dasatinib 62 pegylated interferon alfa 2b 62 heavily pretreated patients 62 hormone receptor positive 62 superficial bladder cancer 62 bevacizumab Avastin ® 62 recurrent NSCLC 62 fluorouracil 62 pCR 62 epithelial ovarian cancer 62 paclitaxel carboplatin 62 chemotherapeutic agent 62 Torisel 62 EGFR TKI 62 Accelerated Partial Breast Irradiation 62 non squamous NSCLC 62 hepatocellular carcinoma HCC 62 IV NSCLC 62 sorafenib 62 temozolomide 62 APTIVUS r 62 radiochemotherapy 62 prostate carcinoma 62 fluoropyrimidine 62 antimicrobial prophylaxis 62 F FDG PET 62 dacarbazine 62 follicular NHL 62 FOLFIRI 62 5 FU 62 EUS FNA 62 antiangiogenic therapy 62 pain palliation 62 surrogate endpoint 62 KRAS mutation 62 Taxotere ® 62 posaconazole 62 erlotinib 62 cytotoxic therapy 62 metastases 62 bendamustine 62 androgen deprivation therapy 62 advanced NSCLC 62 metastatic castration resistant 62 therapeutic regimens 62 concurrent chemoradiation 62 adenomatous polyps 62 recurrent metastatic 62 nonmetastatic 62 EGFR mutations 62 virologic failure 62 aromatase inhibitor therapy 62 biologic therapy 61 TORISEL 61 idarubicin 61 imatinib 61 distant metastasis 61 radical cystectomy 61 nephron sparing surgery 61 Surgical resection 61 chemotherapeutic agents 61 renal tumors 61 fallopian tube cancers 61 adjuvant 61 resistant ovarian cancer 61 breast carcinoma 61 radioiodine therapy 61 axitinib 61 beam radiotherapy 61 aromatase inhibitors AIs 61 cediranib 61 anthracyclines 61 warfarin therapy 61 Neoadjuvant 61 metastatic malignant melanoma 61 antithrombotic therapy 61 myeloablative 61 thromboprophylaxis 61 low dose cytarabine 61 axillary lymph node 61 medically inoperable 61 node dissection 61 anthracycline taxane 61 eptifibatide 61 HRPC 61 neoadjuvant chemoradiotherapy 61 taxane chemotherapy 61 malignant pleural mesothelioma 61 iniparib 61 thromboembolic events 61 SLN biopsy 61 5-fluorouracil/leucovorin 61 Radical prostatectomy 61 neoplasia 61 metastatic GIST 61 progression TTP 61 DMARDs 61 thyroid nodules 61 CaP 61 HER2 positive breast cancer 61 randomized trials 61 median PFS 61 nephrectomy 61 antitumor effect 61 tumor histology 61 rituximab 61 contralateral breast 61 receptor tyrosine kinase inhibitor 61 fallopian tube carcinoma 61 free survival PFS 61 aromatase inhibitor 61 radiation therapy 61 monotherapy 61 docetaxel Taxotere ® 61 infusional 5-FU/LV 61 partial nephrectomy 61 liver metastasis 61 YONDELIS 60 empiric therapy 60 anastrozole 60 HER2 positive cancers 60 palliation 60 intravenous bisphosphonates 60 parathyroidectomy 60 CMV disease 60 dose dexamethasone 60 standard chemotherapy regimen 60 R0 resection 60 Recurrence Score 60 invasive carcinoma 60 dose cytarabine 60 BCG refractory 60 HNSCC 60 alkylating agent 60 chemotherapy docetaxel 60 immunosuppressive agents 60 gefitinib Iressa 60 paroxysmal AF 60 DMARD therapy 60 Irinotecan 60 thalidomide Thalomid 60 pT2 60 transurethral resection 60 axillary nodes 60 MAGE A3 ASCI 60 XELOX 60 cilengitide 60 immunosuppressive regimens 60 thrombolytic therapy 60 immunomodulatory therapy 60 goserelin 60 pulmonary metastases 60 abiraterone acetate 60 nodal metastases 60 endarterectomy 60 refractory AML 60 orchiectomy 60 PCa 60 GP IIb IIIa inhibitors 60 dual antiplatelet therapy 60 chemotherapies 60 castration resistant prostate cancer 60 Subgroup analyzes 60 dosage regimens 60 β blockers 60 Fludara 60 temozolomide TMZ 60 cervical carcinoma 60 intraperitoneal chemotherapy 60 overlapping toxicities 60 ovarian carcinoma 60 hepatocellular carcinoma 60 radical prostatectomy RP 60 advanced adenomas 60 prostate cancer PCa 60 Zevalin consolidation 60 estrogen receptor negative 60 EGFR mutation 60 FOLFOX6 60 oophorectomy 60 hormone receptor negative 60 HSCT 60 gemcitabine carboplatin 60 Erlotinib 60 sipuleucel T 60 histologically confirmed 60 unfractionated heparin 60 enzastaurin 60 topotecan 60 prognostic indicator 60 lenalidomide dexamethasone 60 tumor shrinkage 60 recurrent ovarian 60 metastatic HRPC 60 H. pylori eradication 60 precursor lesions 60 bone metastasis 60 EFAPROXYN 60 oral Xeloda 60 prognostic indicators 60 remission induction 60 adenoma recurrence 60 docetaxel Taxotere 60 mTOR inhibitors 60 calcineurin inhibitors 60 statin therapy 60 letrozole 60 VTE prophylaxis 60 antidepressant therapy 60 bladder carcinoma 60 flutamide 60 esophagectomy 60 contralateral breast cancer 60 capecitabine 60 metastatic melanoma 60 APPRAISE 60 multimodality therapy 60 mitoxantrone 60 allogeneic SCT 60 irinotecan chemotherapy 60 bone metastases 60 differentiated thyroid 59 reperfusion therapy 59 adalimumab 59 carotid artery stenting 59 KRAS mutations occur 59 metastatic lung cancer 59 CHOP chemotherapy 59 surgical excision 59 LHRH receptor positive 59 GnRH agonist 59 completely resected 59 HIPEC 59 Allovectin 7 ® 59 relapsed SCLC 59 Bezielle 59 lymph node metastasis 59 tyrosine kinase inhibitors 59 xenograft models 59 TNF blocker therapy 59 ELOXATIN 59 invasive lobular carcinoma 59 hormone refractory 59 LMWH 59 CsA 59 paclitaxel eluting stents 59 Trastuzumab 59 curative therapy 59 thoracoscopic lobectomy 59 mapatumumab 59 endometrial hyperplasia 59 allogeneic HSCT 59 renal dysfunction 59 polypectomy 59 DAPT 59 WBRT 59 5 fluorouracil 59 NRTIs 59 BRCA deficient 59 underwent resection 59 urothelial carcinoma 59 endocrine therapies 59 hypofractionated 59 aldosterone antagonists 59 revascularization 59 pazopanib 59 surgical resection 59 corticosteroid therapy 59 ribavirin RBV 59 peginterferon 59 urine cytology 59 epithelial tumors 59 Cisplatin 59 ALA PDT 59 estrogen receptor positive 59 node metastases 59 Pemetrexed 59 biochemical relapse 59 medullary thyroid cancer 59 CA4P 59 BRCA2 mutation carriers 59 trastuzumab Herceptin 59 OPAXIO 59 trastuzumab Herceptin R 59 immunosuppressive regimen 59 hepatic resection 59 #F FDG PET 59 antiretroviral regimen 59 endosonography 59 etoposide 59 oral anticoagulation 59 metastatic liver 59 nodal dissection 59 oral deforolimus 59 preoperative radiotherapy 59 FDG-PET/CT 59 patients undergoing CABG 59 abciximab 59 lintuzumab 59 doxorubicin 59 interferon alfa 2a 59 Velcade bortezomib 59 nonoperative treatment 59 mitomycin C 59 ELACYT 59 mammographic density 59 lymph node removal 59 palliative radiotherapy 59 plus dexamethasone 59 nonrandomized 59 trastuzumab Herceptin ® 59 adjuvant endocrine therapy 59 salpingo oophorectomy 59 tirofiban 59 leucovorin 59 Taxotere 59 interferon alfa 59 phosphate binders 59 uric acid lowering 59 oxaliplatin 59 dose escalation 59 rFVIIa 59 prostatectomy 59 eribulin 59 chemoprevention trials 59 EGFR tyrosine kinase inhibitors 59 urothelial bladder cancer 59 Panzem R NCD 59 vaginal hysterectomy 59 olaparib 59 Sentinel node biopsy 59 virologic response 59 PREZISTA r 59 T1a 59 TURBT 59 pomalidomide 59 bevacizumab Avastin Genentech 59 riociguat 59 tocilizumab 59 vicriviroc 59 histologies 59 forodesine 59 cystoscopy 59 adjuvant trastuzumab 59 BRCA mutation carriers 59 cranial radiation 59 colorectal cancer liver metastases 59 Lenalidomide 59 imatinib Gleevec 59 chemoresistant 59 estramustine 59 adjuvant cisplatin 59 eribulin mesylate 59 seminoma 58 Adjuvant therapy 58 decitabine 58 grade gliomas 58 Halaven 58 tumor necrosis 58 prognostic biomarker 58 advanced hepatocellular carcinoma 58 sleeve lobectomy 58 pelvic lymph node dissection 58 fondaparinux 58 bortezomib Velcade 58 anti leukemic 58 tumor lysis syndrome 58 PXD# 58 colectomy 58 adjuvant hormonal therapy 58 antiplatelet drugs 58 adriamycin 58 K ras mutations 58 genotypic resistance 58 erlotinib Tarceva 58 bisphosphonate therapy 58 peritoneal carcinomatosis 58 IV melanoma 58 FOLFIRINOX 58 TRUS biopsy 58 perioperative morbidity 58 Genasense ® 58 anti angiogenic therapy 58 basal cell carcinoma BCC 58 HCV SPRINT 58 adrenalectomy 58 glufosfamide 58 colorectal cancer CRC 58 OncoVEX GM CSF 58 anthracycline containing 58 bilateral oophorectomy 58 antifungal therapy 58 erlotinib Tarceva ® 58 NMIBC 58 zalutumumab 58 Combination therapy 58 resectable pancreatic cancer 58 antiangiogenic agents 58 NNRTI resistance 58 alteplase 58 Gefitinib 58 transplantation HCT 58 methotrexate 58 chemoprevention 58 TKI therapy 58 conventional angiography 58 trans retinoic acid 58 malignancies 58 liposomal amphotericin B 58 coronary revascularization 58 stereotactic radiotherapy 58 chlorambucil 58 gastrointestinal stromal tumor GIST 58 autologous transplants 58 liver transplant recipients 58 risk stratification 58 resected 58 TNF inhibitor 58 immunosuppression 58 androgen suppression therapy 58 azacitidine 58 Hodgkin lymphoma HL 58 mediastinoscopy 58 nomograms 58 NEUVENGE 58 predictive biomarker 58 plus gemcitabine 58 baseline LDH 58 revascularization procedures 58 fine needle aspiration 58 neurologic progression 58 chemotherapeutic regimen 58 HER2 overexpression 58 trastuzumab DM1 58 cabazitaxel 58 Median survival 58 lung metastases 58 unresectable tumors 58 metastatic sarcoma 58 HGS ETR1 58 anticoagulation 58 protease inhibitor PI 58 total thyroidectomy 58 metastatic colorectal 58 EGFR inhibitors 58 treatment regimens 58 dacarbazine chemotherapy 58 recurrent ovarian cancer 58 catheter angiography 58 virologic responses 58 INTELENCE 58 metastatic gastric 58 EGFR mutation positive 58 lymphatic mapping 58 axillary lymph nodes 58 virological response 58 ICD therapy 58 dexamethasone Decadron 58 paricalcitol 58 lupus nephritis 58 stage IIIb IV 58 NovoTTF 58 Kaplan Meier analysis 58 RF ablation 58 oral ridaforolimus 58 Herceptin trastuzumab 58 PROSTVAC ® 58 relapsed MM 58 advanced neoplasia 58 ASCT 58 noninferiority 58 oncologic outcomes 58 BENICAR HCT 58 cisplatin vinorelbine 58 IV bisphosphonates 58 HCV infected 58 paclitaxel Taxol R 58 oral Hycamtin 58 NATRECOR ® 58 prognostic marker 58 exemestane 58 flexible sigmoidoscopy 58 infusional 58 dosing regimens 58 anticoagulant therapy 58 tamsulosin 58 Flu Cy 58 NSABP B 58 antihypertensive agents 58 Gemcitabine 58 metastatic prostate cancer 58 CR nPR 58 excisional biopsy 58 cilostazol 58 depsipeptide 58 taxane 58 fibrinolytic therapy 58 prostate cancer HRPC 58 EGFR TKIs 58 platelet inhibitor 58 renal transplantation 58 chemotherapy 58 pancreatic NET 58 histological subtype 58 T DM1 58 squamous histology 58 nonfatal MI 58 cancer mCRC 58 rt PA 58 clodronate 58 vinorelbine 58 ISTODAX 58 stratifying patients 58 mitomycin 58 resection 58 colorectal cancer 58 stage IIIA 58 adenoma 58 lobectomy 58 disease progression 58 invasive coronary angiography 58 Bortezomib 58 endoscopic ultrasound 57 hydroxychloroquine 57 prespecified 57 estrogen receptor ER 57 elective PCI 57 antiangiogenic agent 57 trials RCTs 57 hormone therapy 57 endometrial cancers 57 capecitabine Xeloda 57 lung resection 57 TEMODAL 57 pamidronate 57 metastatic kidney 57 peg interferon 57 metastatic 57 stratify patients 57 asymptomatic carotid stenosis 57 TTF Therapy 57 DCVax ® Brain 57 axillary node 57 ablative therapy 57 postoperative mortality 57 dasatinib Sprycel ® 57 prior chemotherapy regimens 57 grade cervical intraepithelial 57 RALP 57 thromboembolic disease 57 cetuximab Erbitux 57 eplerenone 57 ibandronate 57 relapsed AML 57 hormone receptor status 57 daunorubicin 57 chemosensitivity 57 CRp 57 GISTs 57 unresectable stage 57 Allovectin 7 57 TroVax ® 57 prophylaxis 57 antitumor activity 57 fibrinolysis 57 bivalirudin 57 biliary tract cancer 57 extracranial 57 pharmacologic intervention 57 refractory CLL 57 antiplatelet agents 57 seminal vesicle invasion 57 severe neutropenia 57 chemo radiotherapy 57 SCCHN 57 sorafenib Nexavar ® 57 localized renal 57 evaluable 57 urothelial cancer 57 NRTI 57 PROSTVAC TM 57 HBeAg seroconversion 57 serum PSA 57 prostate TURP 57 skeletal metastases 57 Hormonal therapy 57 assessing T DM1 57 platelet reactivity 57 paclitaxel Taxol 57 Helicobacter pylori eradication 57 castrate resistant 57 NATRECOR R 57 postoperative morbidity 57 interferon alfa 2b 57 gastric carcinoma 57 pelvic radiotherapy 57 metastatic CRC 57 IMGN# 57 chemopreventive agent 57 HGS# 57 HBeAg positive patients 57 micrometastasis 57 ritonavir boosted 57 doxorubicin docetaxel 57 oral clodronate 57 advanced adenoma 57 Platinol 57 fludarabine 57 recurrent VTE 57 optimal dosing 57 Cytoxan 57 anthracycline therapy 57 Chemophase 57 antiarrhythmic drug 57 luteinizing hormone releasing 57 antiarrhythmic drugs 57 dose cohort 57 xanthine oxidase inhibitor 57 antibiotic therapy 57 antihypertensive therapy 57 core needle biopsy 57 screening mammography 57 predictive biomarkers 57 Faslodex 57 irinotecan 57 lapatinib 57 duplex ultrasonography 57 atypical hyperplasia 57 tanespimycin 57 radioimmunotherapy 57 octreotide 57 HER2 positive tumors 57 oral antiplatelet 57 sustained virological response 57 Tamibarotene 57 carcinoid tumors 57 metastatic bladder 57 autologous transplant 57 tipranavir 57 grade dysplasia 57 premenopausal 57 androgen independent 57 Folfox 57 nodal metastasis 57 DVT prophylaxis 57 everolimus eluting stents 57 liver biopsies 57 metastatic malignant 57 teriflunomide 57 HER2 expression 57 progesterone receptor PR 57 symptomatic VTE 57 enfuvirtide 57 intravesical 57 caspofungin 57 Ceplene/IL-2 57 AGILECT R 57 sunitinib Sutent 57 neratinib 57 Platinol ® cisplatin 57 anticoagulation therapy 57 tiuxetan 57 sentinel node 57 breast irradiation 57 HGPIN 57 SBRT 57 CLL SLL 57 breast cancer subtypes 57 Vectibix monotherapy 57 estrogen therapy 57 lipid lowering drugs 57 aldosterone antagonist 57 colon capsule endoscopy 57 aflibercept 57 surgical revascularization 57 microwave hyperthermia 57 ErbB2 positive 57 5 Fluorouracil 57 achieve sustained virologic 57 histologic subtype 57 endothelin antagonists 57 KRAS mutations 57 cutaneous melanoma 57 Tarceva TM 57 colorectal carcinoma 57 intravenous cyclophosphamide 57 Liver transplantation 57 figitumumab 57 microsphere therapy 57 Elitek 57 metachronous 57 prostatic adenocarcinoma 57 Mitoxantrone 57 gastric adenocarcinoma 57 DOXIL 57 nesiritide 57 adenomatous 57 cytokine refractory 57 hepatectomy 57 cytogenetic response 57 hematologic toxicity 57 nephrotoxicity 57 VATS lobectomy 57 Radiofrequency ablation 57 cisplatin gemcitabine 57 velafermin 57 GP IIb IIIa inhibitor 57 virologic 57 HuMax EGFr 57 mg/m2 dose 57 abdominal hysterectomy 57 oral rivaroxaban 57 GVAX 57 postoperative AF 57 ATACAND 57 paclitaxel cisplatin 57 breast cancer recurrence 57 postoperative complication 57 coronary angiography 57 comorbidities 57 posttransplant 57 complete cytogenetic 57 Xelox 57 refractory CTCL 57 tamoxifen Nolvadex ® 57 transthoracic 57 IRX 2 57 IMC A# 57 intraductal 57 histologic 57 taxanes 57 beta blocker therapy 57 tumor subtypes 57 MMP inhibitors 57 oral antidiabetic medication 57 leukemia AML 57 custirsen 57 low dose dexamethasone 57 perioperative complications 57 BEACOPP 57 arteriography 57 EBUS FNA 57 galiximab 57 refractory colorectal cancer 57 acute leukemias 57 tumor progression TTP 57 weekly subcutaneous injections 57 phase IIb clinical 57 BAY #-# 57 patients evaluable 57 sirolimus eluting stents 56 T2DM 56 gp# vaccine 56 QTc prolongation 56 panobinostat 56 metastatic lesions 56 pegfilgrastim 56 radiation therapy SBRT 56 refractory ovarian cancer 56 sunitinib malate 56 Ceflatonin 56 Telintra 56 ZOLINZA 56 vorinostat 56 boosted protease inhibitor 56 lapatinib Tykerb 56 mg kg dose 56 intravesical chemotherapy 56 glucocorticoids 56 radiotherapy SBRT 56 APTIVUS ritonavir 56 endoscopic resection 56 minimally symptomatic 56 relapsed refractory 56 idraparinux 56 NSTE ACS 56 myeloproliferative diseases 56 graft occlusion 56 antiangiogenic 56 octreotide LAR 56 Temsirolimus 56 HBeAg negative 56 pancreatic carcinoma 56 raltegravir 56 lipid lowering therapies 56 colorectal adenoma 56 cranial irradiation 56 CR# vcMMAE 56 hepatocellular cancer 56 Amrubicin 56 Bevacizumab 56 clinically meaningful 56 FOLFIRI alone 56 mutational status 56 poorer prognosis 56 allogeneic transplantation 56 STRIDE PD 56 Hepatocellular Carcinoma HCC 56 hormone refractory prostate cancer 56 serous ovarian cancer 56 coronary stenting 56 mycosis fungoides 56 letrozole Femara 56 insulin glargine 56 thyroidectomy 56 belinostat 56 CTEPH 56 complete remissions 56 Taxotere chemotherapy 56 NSABP 56 Sunitinib 56 abiraterone 56 carcinoma 56 subcutaneous SC 56 pharmacodynamic PD 56 follicular lymphoma FL 56 balloon brachytherapy 56 Taxotere R 56 intramuscular injections 56 prognostic factor 56 urography 56 virological failure 56 nonoperative 56 immunosuppressant therapy 56 Surgical excision 56 anti TNF 56 TAXOTERE R 56 satraplatin Phase 56 intra arterial chemotherapy 56 postmenopausal estrogen 56 transitional cell carcinoma 56 DLBCL 56 carcinomas 56 complete cytogenetic response 56 scintigraphic 56 ticagrelor 56 abatacept 56 BRIM2 56 immunosuppressive medications 56 cART 56 grade glioma 56 exemestane Aromasin 56 metastatic colon cancer 56 gastrointestinal stromal tumors